Ascletis Pharma, Inc.

China’s biopharma sector is continuing its ascent, with its companies leading the best-performing small-cap publicly-listed companies in the first half of 2025. Data compiled by Evaluate Pharma show C

Among Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-

Sagimet Bioscience’s denifanstat has met all primary, key secondary and secondary endpoints in a Phase III clinical trial in China for the treatment of moderate-to-severe acne vulgaris conducted by gr

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist. Data from the Phase Ib MAD study show the Hong Kong